Biotechnology company Indian Immunologicals (IIL) has announced the commencement of the construction of its new vaccine manufacturing plant at Genome Valley, Hyderabad.

The company is investing around Rs 700 crore in this facility.

Equipped with a BSL3 (biosafety level) facility for drug substance production and a Fill-Finish capability for final vaccine products, the unit will focus on combating two major livestock diseases: Foot and Mouth Disease (FMD) and Haemorrhagic Septicaemia (HS).

Meenesh Shah, Chairman of NDDB stated, 'This new facility reaffirms IIL's dedication to its mission, playing a crucial role in eradicating FMD and HS within our country.'

Anand Kumar, Managing Director of IIL, echoed this sentiment, stating, 'We are at a critical growth phase and anticipate a 40 per cent increase this year alone. This facility paves the way for further investments, contributing to disease control and eradication efforts both in India and across emerging markets.'